Moreover, other studies found that TGF-β1 actually reduced fractalkine mRNA and protein expression in glioma cells [61], which supports a complex interplay between the levels of these two molecules that may be dependent on the tissue or disease of interest. This evidence concerns the gene TGFB1 and central nervous system cancer.